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Background: It is now three decades into the HIV epidemic
whichwas superimposedonanuncontrolledMalariaburden. These
two diseases are of major public health importance and clinical
importance in Sub-saharan Africa and in Nigeria in particular. HIV
and malaria co-infection is common yet surprisingly few clini-
cal associations have been reported in Nigeria. This study aims to
assess Malaria preventive practices and the clinical burden among
HIV infected patients.
Methods & Materials: A cross-sectional descriptive study was
conducted during themonths of January and February 2014 among
356 HIV positive patients attending Nasara clinic of Ahmadu
Bello University Teaching Hospital (ABUTH) Zaria. Ethical approval
was obtained from the Ethical review committee while written
informed consent was obtained from all respondents.A semi-
structured, self-administered questionnaire was used to elicit
information from the respondents. Data was analysed using SPSS
Version 21.
Results: About 99.2% of the respondentswere familliar with the
termMalariawhile90.2%of the respondentsknewthat co-infection
exists betweenMalaria andHIV. However only 36.2% of the respon-
dents had good knowledge ofMalaria and its co-infectionwithHIV.
Majority 93.3%of them had appropriate practice of Malaria preven-
tionwith 96.3%using one ormoremethods of prevention and78.7%
use a prophylactic antimalarial drugs. More than half (54.2%) of the
respondents hadat least an episodeofmalaria in the last sixmonths
while 72.8% have had limitations from carrying out their normal
activities.
Conclusion: This study emphasized that despite a good knowl-
edge of malaria and its preventive practices among respondents,
malaria still remains a common problem faced by HIV patients
resulting to a substantial limitation from carrying out normal phys-
ical activities. It is suggested that the government should initiate,
encourage and sustain focused based campaigns aboutMalaria and
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Background: The isolation of broadly neutralizing antibodies
has been a high priority since they were identiﬁed as potential
targets for passive immunotherapy to slow or halt the disease pro-
gression in HIV-1 infected individuals. Until recently, only a few
recombinant NAbs were available for clinical trials and require-
ment for the identiﬁcation of broadly neutralizing sera from HIV-1
infected individual is still high. Although a few human broadly
neutralizing antibodies to HIV-1 exist, these antibodies have lim-
ited reactivity against non-clade B viruses and so far none of
the broadly neutralizing antibodies isolated from Indian donors.
Here we attempt to identify cross reactive neutralization response
among patients infectedwithHIV-1 subtype C from southern India.
Methods & Materials: We studied HIV-1 neutralizing antibody
(nAb) response in serum among 23 HIV -1 chronically infected
individuals with median CD4 Count 581(IQR 339-786) and Plasma
viral load 15506 (IQR 6944-51308). These individuals were diag-
nosed for HIV between 6 and 10 years and naïve for antiretrovirals.
Neutralization was measured in a single round infection assay in
TZM-bl cells using 19 Tier-II Multi-clade envelope pseudotyped
viruses (Subtype A,B C,AE,BE & G) representing from global virus
panel. Correlation and Neutralization breadth was analyzed using
Spearman’s rank test and p value less than 0.05 was considered
statistically signiﬁcant.
Results: Broad and potent neutralization (ability to neutralize
75% of pseudoviruses) was observed in 5 (22%) individuals (Fig-
ure:1). Interestingly 3 individuals have shown geometric mean
neutralizing titer over 500 and are termed as “elite neutralizers”.
The overall neutralization breadth was positively correlated with
HIV-1 RNA (rho = 0.362, p=0.0089) and negatively correlated with
CD4+ T Cell counts (rho = -0.667, P=0.0004).
Conclusion: This study has witnessed elite neutralizers with
heterologous ‘Tier II viruses’ from southern India. It is evident that
broadly neutralizing specimens can be identiﬁed with larger stud-
ies with further extension to deﬁne epitope speciﬁcities, there by
identifying potential antibodies and epitopes for use in therapeutic
and vaccine trials.
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